zaleplon (Sonata)

From Aaushi
Jump to navigation Jump to search

Introduction

Tradename: Sonata. DEA-controlled substance: class 4.

Indications

Dosage

5-20 mg PO QHS

Tabs: 5 & 10 mg.

Pharmacokinetics

elimination via liver

Adverse effects

* Boxed warning:

  • rare risks for sleepwalking, sleepdriving, & other unusual behaviors (i.e., using a stove while sleeping)[3]

Drug interactions

  • any drug that inhibits cyt P450 3A4 may increase levels of zaleplon
  • any drug that induces cyt P450 3A4 may diminish levels of zaleplon

Mechanism of action

More general terms

References

  1. Drugdex(R) Drug Evaluation
  2. Prescriber's Letter 13(3): 2006 Cytochrome P450 drug interactions Detail-Document#: http://prescribersletter.com/(5bhgn1a4ni4cyp2tvybwfh55)/pl/ArticleDD.aspx?li=1&st=1&cs=&s=PRL&pt=3&fpt=25&dd=220233&pb=PRL (subscription needed) http://www.prescribersletter.com
  3. 3.0 3.1 FDA News Release. April 30, 2019 FDA requires stronger warnings about rare but serious incidents related to certain prescription insomnia medicines. Updated warnings for eszopiclone, zaleplon and zolpidem. https://www.fda.gov/news-events/press-announcements/fda-requires-stronger-warnings-about-rare-serious-incidents-related-certain-prescription-insomnia
  4. Marbin A et al Zaleplon Versus Zolpidem Use in Older Adults Being Treated for Insomnia: A Review. Am J Geriatr Psychiatr. 2023. 31(3)S68-S69 Not indexed in PubMed https://www.sciencedirect.com/science/article/abs/pii/S1064748123000544

Database